Chairman:  Joe Pitts (PA-16)
Public health and quarantine; hospital construction; mental health; biomedical research and development; health information technology, privacy, and cybersecurity; public health insurance (Medicare, Medicaid) and private health insurance; medical malpractice and medical malpractice insurance; the regulation of food, drugs, and cosmetics; drug abuse; the Department of Health and Human Services; the National Institutes of Health; the Centers for Disease Control; Indian Health Service; and all aspects of the above-referenced jurisdiction related to the Department of Homeland Security.



Joe Pitts (PA), Chairman
Brett Guthrie (KY), Vice Chairman
Ed Whitfield (KY)
John Shimkus (IL)
Tim Murphy (PA)
Michael C. Burgess, M.D. (TX)
Marsha Blackburn (TN)
Cathy McMorris Rodgers (WA)
Leonard Lance (NJ)
Morgan Griffith (VA)
Gus Bilirakis (FL)
Billy Long (MO)
Renee Ellmers (NC)
Larry Bucshon (IN)
Susan Brooks (IN)
Chris Collins (NY)
Joe Barton (TX)
Fred Upton (MI) (Ex Officio)


Gene Green (TX), Ranking Member
Eliot L. Engel (NY)
Lois Capps (CA)
Jan Schakowsky (IL)
G. K. Butterfield (NC)
Kathy Castor (FL)
John Sarbanes (MD)
Doris O. Matsui (CA)
Ben Ray Lujan (NM)
Kurt Schrader (OR)
Joseph P. Kennedy, III (MA)
Tony Cardenas (CA)
Frank Pallone, Jr. (NJ) (Ex Officio)

January 27, 2014 | Press Release

Presidential Ally Moran on the State of Obamacare: “I don't think we're going to get enough young people signing up to make this bill work”

January 23, 2014 | ICYMI

Health Law’s Uncertainty And Disastrous Rollout Raises More Concerns About Future of Health Care in America

Upton: “Moody’s latest downgrade is further evidence that the president’s health law is not the right prescription for reform.”

January 22, 2014 | Press Release

WASHINGTON, DC – House Energy and Commerce Committee Chairman Fred Upton (R-MI), today led a group of House and Senate Republican lawmakers in sending a letter to Food and Drug Administration (FDA) Commissioner Margaret Hamburg expressing concerns about the FDA

January 22, 2014 | Letter

Excerpt: We are writing to express grave concerns regarding a regulation … that would change longstanding policy regarding the 1984 Hatch-Waxman Act. The proposed regulation would allow generic manufacturers to alter an abbreviated new drug application (ANDA) label without the FDA’s prior approval.

January 21, 2014 | Blog Post

With or Without Enrollment Figures as a Measure for Success, Health Law Continues to Fall Short  

January 17, 2014 | Blog Post

UPTON: “Delaying the individual mandate was the right policy six months ago, and it is still the right policy today.”